TLR4-IN-C34 is primarily used as a selective inhibitor of the TLR4 signaling pathway, which plays a key role in innate immunity and inflammation. It is applied in research settings to modulate inflammatory responses mediated by TLR4 activation, particularly in studies related to sepsis, neuroinflammation, and autoimmune diseases. By suppressing TLR4-driven cytokine production, such as TNF-α and IL-6, it helps in dissecting the role of this receptor in disease models. Its use enables investigation into potential therapeutic strategies for conditions involving chronic inflammation, including metabolic disorders and neurodegenerative diseases like Alzheimer's. TLR4-IN-C34 is also valuable in validating TLR4 as a drug target in preclinical studies.